Skip to Content

Laquinimod FDA Approval Status

FDA Approved: No
Generic name: laquinimod
Company: Teva Pharmaceutical Industries Ltd. and Active Biotech
Treatment for: Multiple Sclerosis, Huntington's Disease

Laquinimod is an oral, CNS-active immunomodulator in development for the treatment of relapsing-remitting multiple sclerosis (RRMS), primary-progressive multiple sclerosis (PPMS) and Huntington disease.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.